“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation , October 4, 2024: a state-of-the-art review which summarizes the current understanding of the mechanism of action of sotatercept, the impact on outcomes that improve how patients feel, function, and survive, and the safety and […]

“A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension”, The Journal of Heart and Lung Transplantation, October 4, 2024 Read Post »

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024

A new study published in Acta cardiologica on October 4, 2024, reviews the current evidence on sotatercept and provides a Belgian perspective on its place in the future treatment strategy for pulmonary arterial hypertension. We are delighted to see that two patients from Belgium are included as co-authors. Wendy Vansteenkiste is the President of the

A Belgian consensus paper on sotatercept for the treatment of pulmonary arterial hypertension, “Acta Cardiologica”, October 4, 2024 Read Post »

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024

The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results. New research published in The Lancet suggests that the seratonin pathway might not be a suitable option for pulmonary arterial hypertension therapy. ELEVATE-2 was a

New research suggests that the serotonin pathway might not be a suitable option for pulmonary arterial hypertension therapy, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024

An article titled “Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review”, was recently published in the European Respiratory Review. It investigates medication adherence (MA) in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The authors note that while it

Medication adherence in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), European Respiratory Review, September 2024 Read Post »

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024

In pulmonary arterial hypertension lung samples researchers have observed elevated asporin levels and found a link between these levels and lower disease severity. Higher levels of asporin appeared to counteract the pathological remodeling of the pulmonary vasculature that characterizes pulmonary arterial hypertension. Jason Hong, MD, PhD, assistant clinical professor at David Geffen School of Medicine

New study finds that elevated “asporin” levels in pulmonary arterial hypertension lung samples are linked to lower disease severity, Healio news, October 2, 2024 Read Post »

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024

MK-5475 is an experimental soluble guanylate cyclase stimulator which is administered via dry powder inhalation and is designed to potentially mitigate the side effects associated with systemic vasodilation. The results of the INSIGNIA-PAH study published in the Respiratory Journal suggest that MK-5475 reduced pulmonary vascular resistance (PVR) and was well tolerated in patients with pulmonary

Results of the INSIGNIA-PAH study on MK-5475, an inhaled soluble guanylate cyclase stimulator for pulmonary arterial hypertension, published on the ERS Respiratory Journal, Vol 64 Issue 3, 2024 Read Post »

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024

Janssen-Cilag International NV, a Johnson & Johnson company, announced on September September 30, 2024, that the European Commission has approved Yuvanci®, a single tablet macitentan 10 mg and tadalafil 40 mg combination therapy for the long-term treatment of adult pulmonary arterial hypertension patients in WHO Functional Class II-III, who are treated with macitentan and tadalafil

Single tablet combination macitentan and tadalafil for pulmonary arterial hypertension (PAH) receives EU Commission approval, September 30, 2024 Read Post »

Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in pulmonary arterial hypertension, September 27, 2024

CS1 is a HDAC, Histone Deacetylase inhibitor, that works through epigenetic modulation and is being developed by Cereno Scientific as a disease modifying treatment for pulmonary arterial hypertension. CS1 targets the root cause of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. The Phase IIa trial evaluated the safety,

Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in pulmonary arterial hypertension, September 27, 2024 Read Post »

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024

Article exploring the serotonin pathway in pulmonary arterial hypertension care published in The Lancet Respiratory Medicine on September 19, 2024, titled “Serotonin pathway blockade in pulmonary arterial hypertension”. The author is Marcin Kurzyna, MD, PhD, FESC Citation Serotonin pathway blockade in pulmonary arterial hypertension, Kurzyna, Marcin, The Lancet Respiratory Medicine, Volume 0, Issue 0, DOI: 10.1016/S2213-2600(24)00291-1

“Serotonin pathway blockade in pulmonary arterial hypertension”, The Lancet Respiratory Medicine, September 19, 2024 Read Post »

Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024

The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is the object of an article published in “Blood Reviews” on 4 September 2024 which examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of drug-drug interactions within the current

Oral anticoagulant treatment in the era of multi-drug therapies for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Blood Review, September 4, 2024 Read Post »

Merck receives European Commission Approval for WINREVAIR™ (sotatercept) for the treatment of pulmonary arterial hypertension, August 26, 2024

Merck, known as MSD outside of the US and Canada, announced on August 26, 2024 that the European Commission has approved WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of pulmonary arterial hypertension in adult patients with World Health Organization (WHO) Functional Class (FC) II to III, to improve

Merck receives European Commission Approval for WINREVAIR™ (sotatercept) for the treatment of pulmonary arterial hypertension, August 26, 2024 Read Post »

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Liquidia Corporation announced on August 20, 2024, that the US Food and Drug Administration (FDA) has granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is supported by the Phase 3 INSPIRE trial, which demonstrated YUTREPIA’s safety and tolerability.

U.S. Food and Drug Administration (FDA) grants tentative approval of YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine”

Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus. The

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, “Respiratory Medicine” Read Post »

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has granted orphan drug designation to ZMA001,a first-in-class therapeutic monoclonal antibody designed to control or inhibit inflammation responses in pulmonary blood vessels. ZMA001 could potentially improve both the survival rates and the quality of life of patients by addressing the underlying cause of pulmonary arterial hypertension. The placebo-controlled

The US Food and Drug Administration (FDA) grants orphan drug designation to ZMA001, a monoclonal antibody being developed as a first-in-class treatment for pulmonary arterial hypertension Read Post »

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024

Selexipag shows promise for treating pulmonary arterial hypertension associated with connective tissue disease (CTD). The ongoing EXPOSURE (EUPAS19085) study sheds light on the real-world management of PAH-CTD patients in Europe and Canada. For more detailed insights, check out the full study results at this link on PubMed Citation Gaine S, Escribano-Subias P, Muller A, Fernandes

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from the EXPOSURE study, Pulmonary Circulation, July 28 2024 Read Post »

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024

Sotatercept, an activin signaling inhibitor, has been recently approved by the FDA for treating pulmonary arterial hypertension (PAH) (see our recent article about the FDA approval at this link), based on two pivotal clinical trials. The authors of the article titled “How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024 Read Post »

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK

The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK Read Post »

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024

A recent article in “Pulmonary Hypertension News” reports on the tentative approval of Alembic Pharmaceuticals’ generic selexipag as pulmonary arterial hypertension treatment for pulmonary arterial hypertension. Alembic’s generic selexipag contains the same chemical substance as an approved treatment, Uptravi for injection, sold by Johnson & Johnson. Selexipag is a prostacyclin receptor agonist that leads to

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024 Read Post »

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial

Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial Read Post »

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept)

On 28 June 2024 the European Medicines Agency has issued a press release to say that the CHMP (human medicines committee) has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity. This is the first step

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept) Read Post »

TRANSLATE »
Scroll to Top